Recombinant multi-species PNPLA6 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PNPLA6 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a phospholipase that deacetylates intracellular phosphatidylcholine to produce glycerophosphocholine. It is thought to function in neurite outgrowth and process elongation during neuronal differentiation. The protein is anchored to the cytoplasmic face of the endoplasmic reticulum in both neurons and non-neuronal cells. Mutations in this gene result in autosomal recessive spastic paraplegia, and the protein is the target for neurodegeneration induced by organophosphorus compounds and chemical warfare agents. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2009]
The Alternative Names of target: BNHS,LNMS,MSws,NTE,NTEMND,Neuropathy target esterase,Nte,OMCS,PNPLA6,Patatin-like phospholipase domain-containing protein 6,Pnpla6,RGD1564611,SPG39,iPLA2delta,sws

Target products collectionGo to PNPLA6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0156-Ag-1/ GM-Tg-hg-IP0156-Ag-2 Human PNPLA6 protein Human
GM-Tg-rg-IP0156-Ag-1/ GM-Tg-rg-IP0156-Ag-2 Rat PNPLA6 protein Rat
GM-Tg-mg-IP0156-Ag-1/ GM-Tg-mg-IP0156-Ag-2 Mouse PNPLA6 protein Mouse
GM-Tg-cynog-IP0156-Ag-1/ GM-Tg-cynog-IP0156-Ag-2 Cynomolgus/Rhesus macaque PNPLA6 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0156-Ag-1/ GM-Tg-felg-IP0156-Ag-2 Feline PNPLA6 protein Feline
GM-Tg-cang-IP0156-Ag-1/ GM-Tg-cang-IP0156-Ag-2 Canine PNPLA6 protein Canine
GM-Tg-bovg-IP0156-Ag-1/ GM-Tg-bovg-IP0156-Ag-2 Bovine PNPLA6 protein Bovine
GM-Tg-equg-IP0156-Ag-1/ GM-Tg-equg-IP0156-Ag-2 Equine PNPLA6 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0156-Ag-1/ GM-Tg-hg-IP0156-Ag-2; GM-Tg-rg-IP0156-Ag-1/ GM-Tg-rg-IP0156-Ag-2;
GM-Tg-mg-IP0156-Ag-1/ GM-Tg-mg-IP0156-Ag-2; GM-Tg-cynog-IP0156-Ag-1/ GM-Tg-cynog-IP0156-Ag-2;
GM-Tg-felg-IP0156-Ag-1/ GM-Tg-felg-IP0156-Ag-2; GM-Tg-cang-IP0156-Ag-1/ GM-Tg-cang-IP0156-Ag-2;
GM-Tg-bovg-IP0156-Ag-1/ GM-Tg-bovg-IP0156-Ag-2; GM-Tg-equg-IP0156-Ag-1/ GM-Tg-equg-IP0156-Ag-2
Products Name PNPLA6 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name PNPLA6
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PNPLA6 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.